GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gamida Cell : Amendment to Initial Statement of Beneficial Ownership (Form 3/A)

01/13/2022 | 06:32pm EDT
Ownership Submission
FORM 3/A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Access Industries Holdings LLC
2. Date of Event Requiring Statement (Month/Day/Year)
2022-01-01
3. Issuer Name and Ticker or Trading Symbol
Gamida Cell Ltd. [GMDA]
(Last) (First) (Middle)
40 WEST 57TH ST, 28TH FL ,
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
2022-01-11
(Street)
NEW YORK NY 10019
6. Individual or Join/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Date Exercisable and Expiration Date 3. Title and Amount of Securities Underlying Derivative Security 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 6. Nature of Indirect Beneficial Ownership
Date Exercisable Expriation Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Access Industries Holdings LLC
40 WEST 57TH ST, 28TH FL

NEW YORK, NY10019

X

Clal Biotechnology Industries Ltd.
3 AZRIELI CENTER TRIANGLE TOWER,
45TH FLOOR, 132 MENACHEM BEGIN ST.
TEL AVIV, L36702301



Affiliate of 10% Owner
Bio Medical Investment (1997) Ltd.
3 AZRIELI CENTER TRIANGLE TOWER,
45TH FLOOR, 132 MENACHEM BEGIN ST.
TEL AVIV, L36702301



Affiliate of 10% Owner
ACCESS INDUSTRIES, LLC
40 WEST 57TH ST, 28TH FL

NEW YORK, NY10019

X

ACCESS INDUSTRIES MANAGEMENT, LLC
40 WEST 57TH ST, 28TH FL

NEW YORK, NY10019

X

Blavatnik Len
40 WEST 57TH ST, 28TH FL

NEW YORK, NY10019

X

AI Gamida Holdings LLC
40 WEST 57TH ST, 28TH FL

NEW YORK, NY10019



Affiliate of 10% Owner
Signatures
/s/ Alejandro Moreno for Access Industries Holdings LLC 2022-01-13
**Signature of Reporting Person Date
/s/ Ofer Gonen (CEO) and Assaf Segal (CFO) for Clal Biotechnology Industries Ltd. 2022-01-13
**Signature of Reporting Person Date
/s/ Ofer Gonen (Director) and Assaf Segal (Director) for Bio Medical Investment (1997) Ltd. 2022-01-13
**Signature of Reporting Person Date
/s/ Alejandro Moreno for Access Industries, LLC 2022-01-13
**Signature of Reporting Person Date
/s/ Alejandro Moreno for Access Industries Management, LLC 2022-01-13
**Signature of Reporting Person Date
/s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik 2022-01-13
**Signature of Reporting Person Date
/s/ Alejandro Moreno for AI Gamida Holdings LLC 2022-01-13
**Signature of Reporting Person Date
Explanation of Responses:
(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer

Gamida Cell Ltd. published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 23:31:01 UTC.


© Publicnow 2022
All news about GAMIDA CELL LTD.
05/17Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences..
BU
05/12GAMIDA CELL LTD. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/10TRANSCRIPT : Gamida Cell Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
CI
05/03Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
BU
04/27Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study..
BU
04/27Gamida Cell Ltd. Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 ..
CI
More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations
Financials (USD)
Sales 2022 1,55 M - -
Net income 2022 -77,2 M - -
Net Debt 2022 62,0 M - -
P/E ratio 2022 -1,82x
Yield 2022 -
Capitalization 132 M 132 M -
EV / Sales 2022 125x
Capi. / Sales 2023 3,90x
Nbr of Employees 167
Free-Float 69,8%
Chart GAMIDA CELL LTD.
Duration : Period :
Gamida Cell Ltd. Technical Analysis Chart | GMDA | IL0011552663 | MarketScreener
Technical analysis trends GAMIDA CELL LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,20 $
Average target price 13,83 $
Spread / Average Target 529%
EPS Revisions
Managers and Directors
Julian Adams Chief Executive Officer & Director
Shai Lankry Chief Financial Officer
Robert I. Blum Chairman
Ronit Simantov Chief Medical & Scientific Officer
Yona Geffen Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
GAMIDA CELL LTD.-13.39%132
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612